公开(公告)号：US10899802B2

公开(公告)日：2021-01-26

申请号：US15728610

申请日：2017-10-10

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Kathrin Ute Jansen ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC: C07K14/22 ,  A61K39/00 ,  C12N7/00 ,  A61K39/13 ,  A61K39/295 ,  A61K39/095 ,  A61K39/12 ,  A61K39/39

Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US20180022783A1

公开(公告)日：2018-01-25

申请号：US15728610

申请日：2017-10-10

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Kathrin Ute Jansen ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC: C07K14/22 ,  A61K39/39 ,  A61K39/295 ,  A61K39/00 ,  A61K39/12 ,  A61K39/095 ,  C12N7/00 ,  A61K39/13

Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US20230414737A1

公开(公告)日：2023-12-28

申请号：US18343968

申请日：2023-06-29

Applicant: PFIZER INC.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Judith Absalon ,  Jose Miguel Aste-Amezaga ,  Johannes Frederik Beeslaar ,  David Cooper ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Isis Kanevsky ,  Lakshmi Khandke ,  Paul Liberator ,  John Lance Perez ,  Lynn Marie Phelan ,  Gary Warren Zlotnick

IPC: A61K39/095 ,  C07K14/22 ,  C07K16/12 ,  A61K47/18 ,  A61K47/10 ,  A61K47/26 ,  A61K31/7028 ,  A61K47/64 ,  A61P31/00 ,  A61K39/12

CPC classification number: A61K39/095 ,  C07K14/22 ,  C07K16/1217 ,  A61K47/183 ,  A61K47/10 ,  A61K47/26 ,  A61K31/7028 ,  A61K47/6415 ,  A61K47/646 ,  A61P31/00 ,  A61K39/12 ,  A61K2039/545

Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

公开(公告)号：US10888611B2

公开(公告)日：2021-01-12

申请号：US15543232

申请日：2016-02-16

Applicant: Pfizer Inc.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC: A61K39/095 ,  A61K47/64 ,  A61K39/00 ,  C07K14/12 ,  A61K39/295 ,  A61K39/12 ,  A61K39/05 ,  A61K39/08 ,  A61K39/04 ,  C07K14/22 ,  A61K47/02 ,  A61K47/22 ,  A61K47/26

Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US09822150B2

公开(公告)日：2017-11-21

申请号：US14470922

申请日：2014-08-27

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Harris ,  Kathrin Ute Jansen ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC: A61K39/00 ,  C07K14/22 ,  A61K39/095 ,  A61K39/12 ,  A61K39/39 ,  C12N7/00 ,  A61K39/13 ,  A61K39/295

CPC classification number: C07K14/22 ,  A61K39/0016 ,  A61K39/095 ,  A61K39/12 ,  A61K39/13 ,  A61K39/295 ,  A61K39/39 ,  A61K2039/5252 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/20034 ,  C12N2770/32634 ,  Y02A50/466

Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US20220401544A1

公开(公告)日：2022-12-22

申请号：US17764153

申请日：2020-09-24

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  John Lance Perez ,  Kathrin Ute Jansen ,  Paul Liberator ,  Cuiwen Tan ,  Thomas Richard Jones ,  Johannes Frederik Beeslaar ,  Judith Absalon ,  Jason Douglas Maguire ,  Shannon Lea Harris

IPC: A61K39/095 ,  A61P31/04 ,  A61K47/02

Abstract: NEW MATERIAL: Recombinant plasmid pTPGIF2 having a size of 4,660 base pairs and a structure obtained by inserting a DNA having a size of 52 base pairs and containing a sequence coding somatostatin into a BamHI incision site of a plasmid vector pTP70-1 capable or fusing a heteropeptide to a carboxy-terminal of a dihydrofolic acid reductase gene of E. coli. USE: Producton of fused protein containing somatostatin.
PREPARATION: A somatostatin gene is integrated into a plasmid vector pTP70-1. pTPGIF2 is kept in stable state when introduced into E. coli. C600 strain. The E. coli. C600 train containing pTPGIF2 is deposited in Fermentation Research institute as FERM BP-1577.

公开(公告)号：US20210085773A1

公开(公告)日：2021-03-25

申请号：US17114802

申请日：2020-12-08

Applicant: Pfizer Inc.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC: A61K39/095 ,  A61K39/00 ,  C07K14/22 ,  A61K39/295 ,  A61K47/64 ,  A61K39/12 ,  A61K47/02 ,  A61K47/22 ,  A61K47/26

Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US20200164056A1

公开(公告)日：2020-05-28

申请号：US16704701

申请日：2019-12-05

Applicant: PFIZER INC.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Judith Absalon ,  Jose Miguel Aste-Amezaga ,  Johannes Frederik Beeslaar ,  David Cooper ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Isis Kanevsky ,  Lakshmi Khandke ,  Paul Liberator ,  John Lance Perez ,  Lynn Marie Phelan ,  Gary Warren Zlotnick

IPC: A61K39/095 ,  A61P31/00 ,  A61K47/64 ,  A61K31/7028 ,  A61K47/26 ,  A61K47/10 ,  A61K47/18 ,  C07K16/12 ,  C07K14/22 ,  A61K39/12

Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

公开(公告)号：US20190231861A1

公开(公告)日：2019-08-01

申请号：US16196150

申请日：2018-11-20

Applicant: PFIZER INC.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Judith Absalon ,  Jose Miguel Aste-Amezaga ,  Johannes Frederik Beeslaar ,  David Cooper ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Isis Kanevsky ,  Lakshmi Khandke ,  Paul Liberator ,  John Lance Perez ,  Lynn Marie Phelan ,  Gary Warren Zlotnick

IPC: A61K39/095 ,  A61K31/7028 ,  C07K14/22 ,  A61K47/26 ,  A61K47/64 ,  A61K47/18 ,  C07K16/12 ,  A61P31/00 ,  A61K47/10

Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

公开(公告)号：US20180214532A1

公开(公告)日：2018-08-02

申请号：US15883334

申请日：2018-01-30

Applicant: PFIZER INC.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Judith Absalon ,  Jose Miguel Aste-Amezaga ,  Johannes Frederik Beeslaar ,  David Cooper ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Isis Kanevsky ,  Lakshmi Khandke ,  Paul Liberator ,  John Lance Perez ,  Lynn Marie Phelan ,  Gary Warren Zlotnick

IPC: A61K39/095 ,  C07K14/22 ,  C07K16/12 ,  A61K31/7028 ,  A61K47/10 ,  A61K47/26 ,  A61K47/18

CPC classification number: A61K39/095 ,  A61K31/7028 ,  A61K47/10 ,  A61K47/183 ,  A61K47/26 ,  A61K47/6415 ,  A61K47/646 ,  A61P31/00 ,  C07K14/22 ,  C07K16/1217

Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.